June 9-10, 2009
The Fairmont Hotel | San Francisco, CA
The march of molecular genomics is progressing from the laboratory to the clinic. Within the pharmaceutical industry, applications of clinical genomics promises to enhance the discovery of drug response markers, reduce the size and expense of clinical drug trials, and provide tools for addressing regulatory approval issues. All agree that applying biological knowledge through prospective genotyping early in clinical trials is necessary, but putting the theory into practice remains a bottleneck. Cambridge Healthtech Institute’s Translating Genomic Knowledge: Biological Discovery to Clinical Utility expounds the driving factors that are encouraging pharmacogenetic strategy development in the pharmaceutical industry.